Human BTLA (31-150) Protein, His Tag (MALS verified)

B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

Product Specifications

Background

Specifications

This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 15.7 kDa. The protein migrates as 27-34 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Accession Number

AAP44003.1

Expression Region

Lys 31 - Ser 150

Host

HEK293

Target

BTLA

Conjugation

Unconjugated

Tag

C-10xHis

Source

Human

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Endotoxin

1.0 EU per μg

Purity

90%

Bioactivity

Immobilized Human BTLA (31-150), His Tag (Cat. No. BTA-H52H3) at 5 μg/mL (100 μL/well) can bind Human HVEM, Fc Tag (Cat. No. HVM-H5258) with a linear range of 0.005-0.313 μg/mL (QC tested).